Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis

Key clinical message A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a rel...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2016-04, Vol.4 (4), p.348-350
Main Authors: Rispo, Antonio, Musto, Dario, Imperatore, Nicola, Testa, Anna, Rea, Matilde, Castiglione, Fabiana
Format: Article
Language:English
Subjects:
Acne
Acne pustolosa
adalimumab
Case Report
Case Reports
Drug dosages
Immunotherapy
Inflammation
Inflammatory bowel disease
inflammatory bowel diseases
infliximab
Monoclonal antibodies
Pathogenesis
Patients
Psoriasis
Quality of life
Steroids
tumor necrosis factor alpha
Tumor necrosis factor-TNF
ulcerative colitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3
cites cdi_FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3
container_end_page 350
container_issue 4
container_start_page 348
container_title Clinical case reports
container_volume 4
creator Rispo, Antonio
Musto, Dario
Imperatore, Nicola
Testa, Anna
Rea, Matilde
Castiglione, Fabiana
description Key clinical message A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs. A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs.
doi_str_mv 10.1002/ccr3.520
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4831381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2290037751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3</originalsourceid><addsrcrecordid>eNp1kUtLxDAYRYMoOuiAv0ACbtxUv_SdjSDjEwRBdB3SzBcn0jY1aTv4700ZlXHhKq-Tk0suIccMzhlAfKGUS86zGHbILIYMIuCQ7m7ND8jc-3cAYFDEGYN9chAXwHlYzIi6drKRvVHUNJ2zIzbY9tRq6nFEh1SqFmk3-N7W1ksqdY-OyqWsTTM0sqKmpZJ2QTBdW5t-RYdaoQsbI1Jla9Mbf0T2tKw9zr_HQ_J6e_OyuI8en-4eFlePkUqnrBrzlHPkgJzluWIyr1JVIWaAqdSVKnVeJSqPNXBdJKWu0kwhhiyy4pAtMTkklxtvN1QNLlWI5GQtOmca6T6FlUb8PWnNSrzZUaRlwpKSBcHpt8DZjwF9L97t4NqQWcQxB0iKIpuosw2lnPXeof59gYGYGhFTIyI0EtCT7US_4M__ByDaAGtT4-e_IrFYPCeT8Atgm5f4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290037751</pqid></control><display><type>article</type><title>Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis</title><source>Wiley-Blackwell Open Access Titles</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Rispo, Antonio ; Musto, Dario ; Imperatore, Nicola ; Testa, Anna ; Rea, Matilde ; Castiglione, Fabiana</creator><creatorcontrib>Rispo, Antonio ; Musto, Dario ; Imperatore, Nicola ; Testa, Anna ; Rea, Matilde ; Castiglione, Fabiana</creatorcontrib><description>Key clinical message A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs. A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs.</description><identifier>ISSN: 2050-0904</identifier><identifier>EISSN: 2050-0904</identifier><identifier>DOI: 10.1002/ccr3.520</identifier><identifier>PMID: 27099725</identifier><language>eng</language><publisher>England: John Wiley &amp; Sons, Inc</publisher><subject>Acne ; Acne pustolosa ; adalimumab ; Case Report ; Case Reports ; Drug dosages ; Immunotherapy ; Inflammation ; Inflammatory bowel disease ; inflammatory bowel diseases ; infliximab ; Monoclonal antibodies ; Pathogenesis ; Patients ; Psoriasis ; Quality of life ; Steroids ; tumor necrosis factor alpha ; Tumor necrosis factor-TNF ; ulcerative colitis</subject><ispartof>Clinical case reports, 2016-04, Vol.4 (4), p.348-350</ispartof><rights>2016 The Authors. published by John Wiley &amp; Sons Ltd.</rights><rights>2016. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3</citedby><cites>FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2290037751/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2290037751?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27099725$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rispo, Antonio</creatorcontrib><creatorcontrib>Musto, Dario</creatorcontrib><creatorcontrib>Imperatore, Nicola</creatorcontrib><creatorcontrib>Testa, Anna</creatorcontrib><creatorcontrib>Rea, Matilde</creatorcontrib><creatorcontrib>Castiglione, Fabiana</creatorcontrib><title>Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis</title><title>Clinical case reports</title><addtitle>Clin Case Rep</addtitle><description>Key clinical message A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs. A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs.</description><subject>Acne</subject><subject>Acne pustolosa</subject><subject>adalimumab</subject><subject>Case Report</subject><subject>Case Reports</subject><subject>Drug dosages</subject><subject>Immunotherapy</subject><subject>Inflammation</subject><subject>Inflammatory bowel disease</subject><subject>inflammatory bowel diseases</subject><subject>infliximab</subject><subject>Monoclonal antibodies</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Psoriasis</subject><subject>Quality of life</subject><subject>Steroids</subject><subject>tumor necrosis factor alpha</subject><subject>Tumor necrosis factor-TNF</subject><subject>ulcerative colitis</subject><issn>2050-0904</issn><issn>2050-0904</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kUtLxDAYRYMoOuiAv0ACbtxUv_SdjSDjEwRBdB3SzBcn0jY1aTv4700ZlXHhKq-Tk0suIccMzhlAfKGUS86zGHbILIYMIuCQ7m7ND8jc-3cAYFDEGYN9chAXwHlYzIi6drKRvVHUNJ2zIzbY9tRq6nFEh1SqFmk3-N7W1ksqdY-OyqWsTTM0sqKmpZJ2QTBdW5t-RYdaoQsbI1Jla9Mbf0T2tKw9zr_HQ_J6e_OyuI8en-4eFlePkUqnrBrzlHPkgJzluWIyr1JVIWaAqdSVKnVeJSqPNXBdJKWu0kwhhiyy4pAtMTkklxtvN1QNLlWI5GQtOmca6T6FlUb8PWnNSrzZUaRlwpKSBcHpt8DZjwF9L97t4NqQWcQxB0iKIpuosw2lnPXeof59gYGYGhFTIyI0EtCT7US_4M__ByDaAGtT4-e_IrFYPCeT8Atgm5f4</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Rispo, Antonio</creator><creator>Musto, Dario</creator><creator>Imperatore, Nicola</creator><creator>Testa, Anna</creator><creator>Rea, Matilde</creator><creator>Castiglione, Fabiana</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>201604</creationdate><title>Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis</title><author>Rispo, Antonio ; Musto, Dario ; Imperatore, Nicola ; Testa, Anna ; Rea, Matilde ; Castiglione, Fabiana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acne</topic><topic>Acne pustolosa</topic><topic>adalimumab</topic><topic>Case Report</topic><topic>Case Reports</topic><topic>Drug dosages</topic><topic>Immunotherapy</topic><topic>Inflammation</topic><topic>Inflammatory bowel disease</topic><topic>inflammatory bowel diseases</topic><topic>infliximab</topic><topic>Monoclonal antibodies</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Psoriasis</topic><topic>Quality of life</topic><topic>Steroids</topic><topic>tumor necrosis factor alpha</topic><topic>Tumor necrosis factor-TNF</topic><topic>ulcerative colitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rispo, Antonio</creatorcontrib><creatorcontrib>Musto, Dario</creatorcontrib><creatorcontrib>Imperatore, Nicola</creatorcontrib><creatorcontrib>Testa, Anna</creatorcontrib><creatorcontrib>Rea, Matilde</creatorcontrib><creatorcontrib>Castiglione, Fabiana</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rispo, Antonio</au><au>Musto, Dario</au><au>Imperatore, Nicola</au><au>Testa, Anna</au><au>Rea, Matilde</au><au>Castiglione, Fabiana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis</atitle><jtitle>Clinical case reports</jtitle><addtitle>Clin Case Rep</addtitle><date>2016-04</date><risdate>2016</risdate><volume>4</volume><issue>4</issue><spage>348</spage><epage>350</epage><pages>348-350</pages><issn>2050-0904</issn><eissn>2050-0904</eissn><abstract>Key clinical message A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs. A 22‐year‐old male with extensive steroid‐dependent/azathioprine‐refractory ulcerative colitis and preexistent severe refractory acne pustolosa (AP) was successfully treated with adalimumab for both conditions. Severe AP could be considered a further indication, instead of a relative restriction, to anti‐TNFα in steroid‐dependent IBD patients needing therapy with this class of drugs.</abstract><cop>England</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>27099725</pmid><doi>10.1002/ccr3.520</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-0904
ispartof Clinical case reports, 2016-04, Vol.4 (4), p.348-350
issn 2050-0904
2050-0904
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4831381
source Wiley-Blackwell Open Access Titles; Publicly Available Content Database; PubMed Central
subjects Acne
Acne pustolosa
adalimumab
Case Report
Case Reports
Drug dosages
Immunotherapy
Inflammation
Inflammatory bowel disease
inflammatory bowel diseases
infliximab
Monoclonal antibodies
Pathogenesis
Patients
Psoriasis
Quality of life
Steroids
tumor necrosis factor alpha
Tumor necrosis factor-TNF
ulcerative colitis
title Dramatic improvement of severe acne pustolosa after adalimumab in a patient with ulcerative colitis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A35%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dramatic%20improvement%20of%20severe%20acne%20pustolosa%20after%20adalimumab%20in%20a%20patient%20with%20ulcerative%20colitis&rft.jtitle=Clinical%20case%20reports&rft.au=Rispo,%20Antonio&rft.date=2016-04&rft.volume=4&rft.issue=4&rft.spage=348&rft.epage=350&rft.pages=348-350&rft.issn=2050-0904&rft.eissn=2050-0904&rft_id=info:doi/10.1002/ccr3.520&rft_dat=%3Cproquest_pubme%3E2290037751%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4050-fe6499e90e9166c1a6b4cbee50e4afbc8f6b3c62f09f738fb45ceeadaab905de3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290037751&rft_id=info:pmid/27099725&rfr_iscdi=true